Depo-Provera Shot More Than Tripled Brain Tumor Risk, Study Finds

Women who have used the injectable contraceptive Depo-Provera for over a year may face a 3.5-times greater risk of developing brain tumors known as meningiomas, according to a study published last month. These and similar findings have prompted hundreds of product liability lawsuits against Pfizer, alleging that the company failed to adequately warn patients and doctors about the potential health risks associated with Depo-Provera. 

What Is Depo-Provera?

Depo-Provera (medroxyprogesterone acetate or DMPA) is a long-acting hormonal birth control shot administered once every three months. It prevents pregnancy by suppressing ovulation and altering cervical mucus to make it harder for sperm to reach an egg. First approved in the 1960s, Depo-Provera remains one of the most widely used contraceptive injections worldwide.

Over 74 million women globally use Depo-Provera for pregnancy prevention. Its convenience and reliability have made it a preferred option for those seeking long-term contraception without a daily pill. However, there have been serious concerns raised about the potential link between Depo-Provera and meningioma brain tumors.

Study Links Depo-Provera to Brain Tumor Risk

The peer-reviewed Depo-Provera study, published in the journal Expert Opinion on Drug Safety,  evaluated large-scale healthcare data to assess the risk of brain tumors in women using Depo-Provera. Researchers found a statistically significant association between prolonged Depo-Provera use and the development of meningiomas—tumors that grow in the protective membranes of the brain and spinal cord.

Women who used Depo-Provera for more than 12 months were found to be 3.5 times more likely to develop these tumors compared to users of combined hormonal pills (containing ethinylestradiol and levonorgestrel). These results support earlier findings from the British Medical Journal, which reported an even higher risk increase of 5.6 times.

Legal Action Against Pfizer Gains Momentum

Over 550 lawsuits have been consolidated into a multidistrict litigation (MDL) in federal court. Plaintiffs allege that Pfizer failed to disclose or sufficiently warn about the risk of intracranial meningiomas and other serious side effects tied to long-term Depo-Provera use.

These Depo-Provera lawsuits claim that Pfizer had access to internal data or earlier research suggesting a potential risk, but allegedly did not update product labels or notify prescribing physicians in a timely manner. Key allegations raised against Pfizer include:

• Failure to warn users about Depo-Provera brain tumor risks
• Negligence in monitoring adverse effects post-market
• Misrepresentation of Depo-Provera’s long-term safety profile
• Inadequate labeling and risk disclosures for patients and physicians

While Pfizer has not admitted wrongdoing, the company may be required to produce internal safety data and risk assessments during the litigation process.

Health Complications Allegedly Linked to Depo-Provera Birth Control

Intracranial meningiomas are typically benign tumors, but they can still cause significant complications, depending on their size and location. Potential symptoms of meningiomas include:

• Persistent or worsening headaches
• Vision disturbances (double or blurred vision)
• Cognitive difficulties, memory loss, or confusion
• Seizures and balance issues

In severe cases, intracranial meningiomas allegedly caused by Depo-Provera birth control may require surgery or long-term neurological care.

Other Reported Health Concerns

In addition to potential tumor formation, long-term Depo-Provera use has also been linked to an alleged increased risk of:

• Pseudotumor cerebri: A condition mimicking brain tumor symptoms due to increased intracranial pressure
• Bone mineral density loss: Leading to osteoporosis and higher fracture risk
• Neurological issues: Including hearing loss, migraines, and visual changes

Although not all users experience these issues, plaintiffs in the lawsuits argue they were not sufficiently warned of these risks when deciding on this contraceptive method.

Experts Call for Additional Depo-Provera Research

Researchers behind the Depo-Provera meningioma study emphasize the need for more comprehensive, long-term investigations into the birth control injection’s safety. While the study findings are concerning, causation has not been conclusively proven, and medical professionals urge additional population studies to assess the magnitude and mechanisms of risk.

If future data corroborate the findings of this and previous studies, regulators may consider changes to Depo-Provera’s safety labeling, prescribing guidelines, or post-market surveillance. Label updates could include:

• Stronger warnings about prolonged use
• Tumor risk disclosure for women with a family history of neurological conditions
• Recommendation to limit use beyond 12 months unless no suitable alternatives exist

A Critical Moment for Women’s Health Transparency

This new study linking Depo-Provera to a potential increase in brain tumor risk has sparked serious concerns for patients and healthcare providers alike. While the scientific debate continues, the volume of Depo-Provera lawsuits and the depth of the allegations underscore the need for clearer communication surrounding long-term contraceptive risks.